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Impact of hemodialysis on endogenous plasma and muscle car-
nitine levels in patients with end-stage renal disease.
Background. End-stage renal disease (ESRD) patients un-
dergoing hemodialysis treatment have reduced plasma L-
carnitine levels; however, the relationship between dialysis age
and carnitine status is poorly understood. This study examined
the relationship between duration of dialysis and plasma and
skeletal muscle concentrations of L-carnitine and its esters in
ESRD patients.
Methods. Blood samples were collected from 21 patients at
baseline and throughout the first 12 months of hemodialysis. In 5
patients, muscle samples were obtained after 0, 6, and 12 months
of hemodialysis. Blood and muscle samples were collected from
an additional 20 patients with a mean dialysis age of 5.10 years.
L-carnitine, acetyl-L-carnitine, and total L-carnitine were mea-
sured by high-performance liquid chromatography (HPLC).
Results. The mean ± SD plasma L-carnitine concentration in
ESRD patients who had not yet started hemodialysis was 50.6 ±
20.0 lmol/L. Significantly lower concentrations were observed
after 12 months (29.7 ± 10.5 lmol/L) and >12 months (22.0 ±
5.4 lmol/L) of hemodialysis treatment. Acetyl-L-carnitine also
declined with dialysis age, while plasma nonacetylated acylcar-
nitines continued to increase with the progression of hemodial-
ysis therapy. An inverse relationship between dialysis age and
muscle L-carnitine concentrations was observed.
Conclusion. Long-term hemodialysis treatment is associated
with a significant reduction in endogenous plasma and muscle
L-carnitine levels and a significant increase in plasma acylcar-
nitines. The majority of the change in plasma L-carnitine con-
centrations occurs within the first few months of hemodialysis,
while muscle levels continue to decline after 12 months of treat-
ment.
L-carnitine is an endogenous substance required for
the transfer of long-chain fatty acids across the inner
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matrix membrane of mitochondria, thereby delivering
these substances for b-oxidation and energy production
[1]. In healthy individuals, blood and tissue levels of L-
carnitine are maintained within relatively narrow limits,
reflecting the importance of the compound in interme-
diate metabolism. The healthy kidney plays a vital role
in this homeostasis, first by conserving body L-carnitine
stores through extensive reabsorption of the filtered load,
and second by preferential excretion of short-chain car-
nitine esters [2, 3].
Patients with end-stage renal disease (ESRD) not un-
dergoing hemodialysis tend to have higher plasma con-
centrations of L-carnitine than healthy individuals [4, 5,
6, 7]. In contrast, a large number of studies have reported
low plasma and muscle L-carnitine levels in ESRD pa-
tients undergoing chronic hemodialysis [2, 3, 8]. This de-
pletion in L-carnitine has been found to correlate with
the length of time over which a patient has been under-
going hemodialysis—that is, their dialysis age, or dialy-
sis vintage [4, 5, 6, 9, 10]. The decrease in endogenous
L-carnitine concentrations that occurs during chronic
hemodialysis is mainly due to the efficient removal of
the compound via the dialysate, possibly coupled with a
reduction in L-carnitine input via dietary intake and en-
dogenous synthesis [2, 8, 11]. However, little is known
about the time-course of L-carnitine in plasma and mus-
cle during the first 12 months of hemodialysis and how
these levels compare with concentrations in patients who
have been receiving hemodialysis treatment for more
than 12 months. With the approved clinical use of supple-
mental L-carnitine for the treatment of dialysis-related
secondary carnitine deficiency and the clinical symptoms
that have been associated with this disorder [8, 12], it is
vital that the temporal relationship between dialysis age
and carnitine status is examined.
In the present study, patients with ESRD were re-
cruited prior to the time at which hemodialysis treat-
ment was first initiated. In these patients, plasma and
skeletal muscle levels of L-carnitine and its esters were
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examined over the first 12 months of hemodialysis treat-
ment. L-carnitine levels were also determined in an addi-
tional group of ESRD patients who had been undergoing
hemodialysis for more than 12 months. The primary ob-
jective of the study was to examine the relationship be-
tween plasma and skeletal muscle levels of L-carnitine,
acetyl-L-carnitine, and total L-carnitine, and the duration
of hemodialysis treatment. Additionally, changes in the
contribution of nonacetylated forms of acylcarnitines to
the total carnitine concentration were also evaluated.
METHODS
Study design
This study was conducted with the approval of the
institutional human research ethics committees, and all
patients provided written informed consent prior to
participation. The patient population comprised 2 co-
horts of adult men and women diagnosed with ESRD—
21 patients were studied over the first 12 months of
hemodialysis treatment (longitudinal component), and
20 patients who had been undergoing hemodialysis for
more than 12 months were studied on one occasion only
(single-session component).
Longitudinal component. Potential subjects were
identified prior to the initiation of hemodialysis treat-
ment. In order to be eligible for this component of the
study, patients were required to be diagnosed with ESRD,
and were expected to require hemodialysis for at least
12 months. Patients were not suitable if they had previ-
ously been receiving continuous ambulatory peritoneal
dialysis (CAPD) or hemodialysis. Patients were excluded
if they had used any products containing L-carnitine
(and/or carnitine derivatives) during the 4 months prior
to screening or throughout the course of the study. Any
patient with a bleeding disorder or who was receiving
anticoagulant therapy was excluded from the muscle
biopsy-sampling component of the study.
Predialysis blood samples (2 mL) were collected from
the inflow to the dialyzer prior to the first dialysis ses-
sion, before the second and third dialysis sessions in the
first week, and then prior to the second dialysis session
of weeks 2, 3, 4, and months 2, 4, 6, 9, and 12. In a sub-
set of consenting patients, a small sample (approximately
15 to 20 mg) of skeletal muscle was collected from the
quadriceps prior to the first hemodialysis session, and
after approximately 6 and 12 months of hemodialysis
treatment. Muscle biopsies were performed by an ap-
propriately trained physician using a Bard Max Core
Disposable Biopsy Instrument (CR Bard, Inc., Coving-
ton, GA, USA). Vital signs were measured prior to and
following muscle biopsy collection for safety monitoring.
Single-session component. An additional group of 20
ESRD patients who had been undergoing hemodialysis
for more than 12 months were recruited to participate in
the single-session component of the study. Patients who
had used L-carnitine (and/or carnitine derivatives) in the
previous 4 months, were receiving anticoagulant therapy,
or were diagnosed with a bleeding disorder were excluded
from the single-session component of the study.
From eligible patients, a predialysis blood sample was
collected from the inflow of the dialyzer during a sin-
gle (mid-week) hemodialysis session. In addition, a single
muscle biopsy sample was collected using the technique
described above within 3 days of the patient’s correspond-
ing blood sample collection.
Analytical methods
Plasma and muscle homogenate concentrations of
(free) L-carnitine and acetyl-L-carnitine were deter-
mined by high-performance liquid chromatography
(HPLC) based on a previously described analytical
method [13, 14], and utilizing the muscle preparation
steps described by Cederblad et al [15]. In addition, to-
tal L-carnitine was measured as L-carnitine after alkaline
hydrolysis of esterified L-carnitine. The method involved
purification by solid-phase extraction, derivatization, and
fluorescence detection of HPLC eluant. The limits of
quantification for plasma L-carnitine, acetyl-L-carnitine,
and total L-carnitine were 2.5, 0.5, and 2.5 lmol/L, re-
spectively. Muscle L-carnitine, acetyl-L-carnitine, and to-
tal L-carnitine limits of quantification were 0.25, 0.1,
and 0.5 lmol/g of homogenized muscle. Quality control
samples analyzed routinely with each analytical run re-
turned mean measured concentrations relative to nomi-
nal values and precision values of within 10% and 8% for
plasma and muscle, respectively. Acylcarnitines were cal-
culated by subtraction of L-carnitine from total carnitine.
Nonacetylated forms of acylcarnitines were derived by
subtraction of acetyl-L-carnitine from the acylcarnitines
level.
Plasma L-carnitine, acetyl-L-carnitine, and total L-
carnitine concentrations were also obtained for a cohort
of healthy volunteers (30 males and 30 females) with a
mean age of 39 years. The normal range for each analyte
was taken to be the 25th and 75th percentiles of the data
obtained from these healthy volunteers.
Statistical methods
Statistical comparisons were performed using analy-
sis of variance (ANOVA) with post-hoc analysis (con-
trasts) if significance was detected. Significance was
set at P < 0.05. WinNonlin Professional, Version 4.0
(Pharsight Corporation, Mountain View, CA, USA) was
used for all statistical analyses. In order to examine the
effect of hemodialysis on plasma and skeletal muscle
L-carnitine, acetyl-L-carnitine, and total L-carnitine con-
centrations, baseline levels (prior to the first hemodial-
ysis session) were compared to those measured at each
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Table 1. Mean ± SD (range) subject demographic data
ESRD patients
Parameter Healthy adults Longitudinal Single-session
No. of subjects 60 21 20
Age years 39 ± 13 (18-75) 51 ± 13 (23-78) 55 ± 14 (27-78)
Gender 30 m, 30 f 13 m, 8 f 12 m, 8 f
Weight kg Not recorded 79 ± 21 (53-125) 71 ± 27 (36-146)
Height cm Not recorded 169 ± 11 (151-190) 165 ± 12 (148-180)
Dialysis age years 0 0 5.10 ± 4.02 (1.25-16.92)
Data were recorded at the time of screening.
Table 2. Mean ± SD (range) dialysis prescription details at each nominal dialysis session
Dialysis session No. of subjects Duration of dialysis session hours Blood flow rate mL/min Dialysate flow rate mL/min
Longitudinal patients
Week 1 DS1 21 2.08 ± 0.26 (1.92-3.17) 164 ± 21 (100-200) 500 ± 0 (500-500)
Week 1 DS2 21 2.55 ± 0.23 (2.00-3.13) 173 ± 25 (100-200) 500 ± 0 (500-500)
Week 1 DS3 21 3.12 ± 0.48 (2.50-5.00) 192 ± 30 (150-290) 500 ± 0 (500-500)
Week 2 DS2 18 3.37 ± 0.36 (2.58-4.00) 194 ± 25 (133-250) 500 ± 0 (500-500)
Week 3 DS2 18 3.86 ± 0.29 (3.50-4.27) 211 ± 37 (160-325) 500 ± 0 (500-500)
Week 4 DS2 20 3.85 ± 0.38 (2.50-4.17) 226 ± 48 (150-350) 500 ± 0 (500-500)
Month 2 DS2 20 3.96 ± 0.30 (3.47-4.58) 244 ± 49 (160-350) 500 ± 0 (500-500)
Month 4 DS2 19 4.18 ± 0.65 (2.25-5.08) 272 ± 50 (167-400) 516 ± 69 (500-800)
Month 6 DS2 18 4.35 ± 0.59 (3.32-5.33) 298 ± 43 (200-400) 533 ± 97 (500-800)
Month 9 DS2 18 4.52 ± 0.62 (3.50-5.77) 308 ± 53 (240-450) 535 ± 100 (500-800)
Month 12 DS2 18 4.28 ± 0.58 (3.08-5.22) 282 ± 75 (100-450) 535 ± 100 (500-800)
Single-session patients
>12 months 20 3.97 ± 0.73 (2.50-5.22) 320 ± 39 (280-400) 560 ± 123 (500-800)
subsequent sample collection time for those patients par-
ticipating in the longitudinal component of the study. In
addition, for each analyte, plasma and muscle levels at
baseline and after 6, 12, and >12 months of dialysis were
compared, and in the case of plasma levels, comparison
with data from 60 healthy adults was also performed.
RESULTS
A total of 41 ESRD patients (25 males, 16 females)
were enrolled into the study. Of these, 21 patients were
enrolled into the longitudinal evaluation and 20 pa-
tients into the single-session evaluation. Eight patients
enrolled in the longitudinal component consented for
muscle biopsy collection, while muscle samples were col-
lected from all patients participating in the single-session
evaluation.
Thirty-eight patients completed the study, with 2 pa-
tients withdrawing due to kidney transplants, and an-
other patient dying from a cerebrovascular event. The
3 patients who did not complete the study were enrolled
in the longitudinal component. An additional 2 patients
were withdrawn from the muscle biopsy component of
the longitudinal evaluation before the 6-month sample
could be collected because they no longer met the in-
clusion/exclusion criteria for muscle biopsy collection.
Demographic data for all subjects, including the healthy
volunteers, are presented in Table 1. During the first
4 months of treatment, the duration of the dialysis ses-
sion, together with the blood flow rate, tended to increase,
thereafter becoming constant (Table 2).
For those subjects who participated in the longitudinal
component of the study, the mean plasma levels of L-
carnitine, acetyl-L-carnitine, and total L-carnitine prior
to the commencement of hemodialysis were 50.6 ± 20.0,
19.8 ± 8.9, and 75.3 ± 21.9 lmol/L, respectively. In com-
parison, the mean levels found in healthy adults were
43.3 ± 8.6, 6.65 ± 2.11, and 49.2 ± 9.3 lmol/L, respec-
tively, with the difference between ESRD patients and
healthy adults being significant (P < 0.05) in all cases
(Table 3). Most notably, the plasma concentration of
acetyl-L-carnitine was almost 3 times higher in the ESRD
patients. It is also notable that while free L-carnitine com-
prised about 88% of the total L-carnitine in the plasma
of healthy adults (12% esterified), in the ESRD patients
only 67% of the total L-carnitine was in the unesterified
form (33% esterified) (Table 3).
In the ESRD patients starting hemodialysis, the pre-
dialysis plasma levels of L-carnitine, acetyl-L-carnitine,
and total L-carnitine had decreased significantly
(P < 0.05) within the first week of hemodialysis treat-
ment, with a continual decline over the first 12 months
of treatment (Fig. 1). After 12 months of dialysis, plasma
L-carnitine, acetyl-L-carnitine, and total L-carnitine had
reached values of 29.7 ± 10.5, 10.0 ± 2.7, and 44.7 ±
11.1 lmol/L, respectively (Table 3). Upon examination
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Table 3. Mean ± SD plasma concentrations (lmol/L) of L-carnitine, acetyl-L-carnitine, and total L-carnitine in healthy adults, and ESRD
patients at baseline and after 6, 12, and >12 months of hemodialysis treatment
ESRD patients
Analyte Healthy adults Baseline 6 months 12 months >12 months
L-carnitine 43.3 ± 8.6b,c,d,e 50.6 ± 20.0a,c,d,e 34.6 ± 12.9a,b,d,e 29.7 ± 10.5a,b,c 22.0 ± 5.4a,b,c
Acetyl-L-carnitine 6.65 ± 2.11b,c,d,e 19.8 ± 8.9a,c,d,e 12.4 ± 4.7a,b,d 10.0 ± 2.7a,b,c 9.23 ± 3.47a,b
Total L-carnitine 49.2 ± 9.3b 75.3 ± 21.9a,c,d,e 48.9 ± 18.5b 44.7 ± 11.1b 42.6 ± 11.9b
a Compared to healthy adults, P < 0.05.
bCompared to ESRD patients at baseline, P < 0.05.
cCompared to ESRD patients after 6 months of dialysis, P < 0.05.
dCompared to ESRD patients after 12 months of dialysis, P < 0.05.
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Fig. 1. Mean ± SEM plasma concentrations of L-carnitine (upper
panel), acetyl-L-carnitine (middle panel), and total L-carnitine (lower
panel) in patients with end-stage renal disease (ESRD) during the first
12 months of hemodialysis treatment. ∗Compared with baseline, P <
0.05.
of data from individual patients from each cohort (lon-
gitudinal and single-session), a clear relationship be-
tween plasma L-carnitine, acetyl-L-carnitine, and total
L-carnitine concentrations and dialysis age is evident,
whereupon the majority of the decrease from baseline
is seen to occur over the first 12 months (Fig. 2). Indeed,
when the patients who had been dialyzed for 12 months
were compared to those who had been undergoing an
average of 5.10 years of treatment, no statistically signifi-
cant differences were detected (Table 3), even though the
mean concentrations were lower for all 3 analytes in the
>12 month group.
In the majority of ESRD patients who had been re-
ceiving hemodialysis for more than 12 months, plasma L-
carnitine levels were substantially lower than the normal
range observed in healthy subjects (37.7 to 48.5 lmol/L),
as shown in Figure 2. Conversely, plasma acetyl-L-
carnitine concentrations in these patients tended in most
cases to be within or higher than the normal range
(5.27 to 8.30 lmol/L), while there was no consistent trend
for total L-carnitine (normal range of 43.1 to 55.3 lmol/L)
once patients had been dialyzed for 12 months. Statisti-
cal comparisons of the various groups (Table 3) confirm
these findings—notably, once patients had been undergo-
ing hemodialysis for 12 months, mean plasma L-carnitine
concentrations were about 30% to 50% below the aver-
age value for healthy subjects, while acetyl-L-carnitine
was about 50% higher than normal, and total L-carnitine
was not significantly different.
By comparing plasma L-carnitine and acetyl-L-
carnitine levels to those of total L-carnitine (Fig. 3), it
is evident that long-term hemodialysis in ESRD patients
is associated with a progressive increase in the relative
contribution of other L-carnitine esters (nonacetyl acyl-
carnitines, which mainly represent medium- and long-
chain acylcarnitines). Indeed, as a percent of the total
plasma carnitine pool, the proportion of these nonacetyl
esters increases from negligible levels in healthy patients
to about 26% in longer-term ESRD patients (Fig. 3). The
accumulation of these esters probably explains why to-
tal L-carnitine levels are relatively normal in long-term
dialysis patients despite a significant reduction in free
L-carnitine (Fig. 2).
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Normal range: 43.1 - 55.3 µmol/L
Fig. 2. Plasma concentrations of L-carnitine (upper panel), acetyl-L-
carnitine (middle panel), and total L-carnitine (lower panel) from lon-
gitudinal () and single-session () patients as a function of dialysis
age.
A clear decline in skeletal muscle L-carnitine, acetyl-
L-carnitine, and total L-carnitine levels was associated
with increasing dialysis age (Fig. 4). In patients who had
been undergoing hemodialysis for more than 12 months,
the average muscle L-carnitine concentration (1.87 ±
0.67 lmol/g) was 38% lower than that in patients who
had not yet started hemodialysis (3.01 ± 0.47 lmol/g)
(Table 4). The duration of dialysis treatment required to
cause a statistically significant decline in skeletal muscle
L-carnitine levels was greater than 12 months, whereas
for acetyl-L-carnitine a significant reduction was detected



















































L-Carnitine Acetyl-L-Carnitine Other carnitines
Fig. 3. The impact of hemodialysis on the relative composition of the
plasma total L-carnitine pool.
DISCUSSION
It has been widely reported that plasma L-carnitine lev-
els in ESRD patients receiving hemodialysis are lower
than in the general population [6, 7, 16–21]. However,
there is very little information on the time frame over
which levels decrease once dialysis therapy commences.
The primary aim of the present study was to closely mon-
itor L-carnitine levels in ESRD patients over their first
12 months of hemodialysis to provide definitive data on
the temporal relationship between dialysis age and the
quantitative and qualitative composition of the plasma
and skeletal muscle pools. The results from these first-
time hemodialysis patients were complemented by data
from ESRD patients receiving long-term (>12 months)
hemodialysis and healthy control patients.
Blood samples collected from the ESRD patients prior
to the first dialysis session gave plasma levels of free L-
carnitine (50.6 lmol/L) that were significantly higher than
healthy adults (43.3 lmol/L). This finding is supported by
other studies in which the impact of renal disease on L-
carnitine levels has been examined, as reviewed recently
by Ahmad [8] and Evans [2]. Once the ESRD patients
commenced hemodialysis (twice or three times a week)
there was a progressive decline in plasma L-carnitine lev-
els (Fig. 1). Plasma L-carnitine concentrations declined
by approximately 30% during the first 4 weeks of dial-
ysis and by 40% over the first 12 months. A previous
study demonstrated a decrease of about 28% over the
first 6 months of hemodialysis treatment [6]. In the cur-
rent study, mean plasma L-carnitine levels in those pa-
tients with a mean dialysis age of 5.10 years (22 lmol/L)
was not significantly different to those patients who had
been dialyzed for 12 months (29.7 lmol/L), suggesting
that the majority of the change occurs during the initial
12 months of hemodialysis. In a study involving a larger
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Fig. 4. Skeletal muscle concentrations of L-carnitine (upper panel),
acetyl-L-carnitine (middle panel), and total L-carnitine (lower panel)
from longitudinal () and single-session () patients as a function of
dialysis age.
cohort (N = 107) of patients who had been undergoing
hemodialysis for 1 to 25 years, Sakurachi et al [10] re-
ported a significant negative correlation between plasma
free L-carnitine levels and months of dialysis. However,
the slope of the regression line in that study was very low,
suggesting a net reduction of only 7 lmol/L over about
20 years of hemodialysis. Taken together with published
data [6, 10], the results of the current study provides com-
pelling evidence that the reduction in plasma L-carnitine
levels in patients receiving chronic hemodialysis occurs
primarily in the first 12 months of dialysis treatment. Af-
ter 12 months, variability between patients tends to ob-
scure any further changes, which may explain the failure
of a previous study [9] to find a statistically significant
correlation between plasma L-carnitine levels and dialy-
sis age—most patients included in this latter study were
long-term (>12 months) dialysis patients.
In a previous study, we demonstrated that there was
no difference in the efficiency with which L-carnitine
and acetyl-L-carnitine are removed from the body by
hemodialysis, with plasma concentrations of both com-
pounds falling by about 70% during a single 3.5-hour
session [13], and this would explain the seemingly par-
allel decline (of about 40% to 50%) in L-carnitine and
acetyl-L-carnitine over the first 12 months of hemodial-
ysis. However, while plasma L-carnitine falls below
normal within the first 6 months of hemodialysis, the
levels of acetyl-L-carnitine actually remain above the
normal range, even in long-term dialysis patients
(Table 3, Fig. 2). Similarly, the acylated forms (excluding
acetyl-L-carnitine) were substantially higher in the long-
term dialysis patients (Fig. 3). The net effect of lower L-
carnitine concentrations and elevated acylcarnitine levels
is that the ESRD patients receiving hemodialysis tend to
have relatively normal total L-carnitine levels in plasma
(Table 3, Fig. 2). While patients commencing dialysis
treatment had minimal residual kidney function, the ef-
fects of worsening kidney disease on the changes in the
carnitine profile during the ensuing hemodialysis period
are unknown.
A large number of studies have measured L-carnitine
and related compounds in human skeletal muscle [9, 15,
17, 18, 22–27]. Direct comparisons between the results
of these studies are complicated by the various reporting
methods (per g wet weight, per g dry weight, per g of non-
collagen protein), as well as differences between the sites
and methods of muscle biopsy sampling [28]. A signifi-
cant reduction in muscle L-carnitine, acetyl-L-carnitine,
and total L-carnitine concentrations were observed as
a function of dialysis age (Table 4). The mean muscle
level of L-carnitine in long-term hemodialysis patients
(>12 months) was 38% lower than the baseline level,
while the acetyl-L-carnitine and total L-carnitine levels
were 52% and 43% lower than the respective values prior
to the commencement of hemodialysis. In keeping with
our findings, in a previous study [18], the muscle con-
centrations of L-carnitine were 36% lower in long-term
dialysis patients compared with healthy control patients.
In patients who had been undergoing hemodialysis for
up to 16 years, a statistically significant negative cor-
relation between muscle total L-carnitine and duration
of dialysis was observed [18], with similar muscle con-
centrations to the present study (1 to 4 lmol/g tissue).
Bellinghieri et al [22] also reported that the levels of
free- and acetyl-L-carnitine in muscle from hemodialy-
sis patients were about half those observed in control
patients, with similar findings being reported by Savica et
al [26]. In the most recent study involving muscle anal-
ysis, De¸bska-Slizien˜ et al [9] reported muscle free and
total L-carnitine levels that were, on average, 30% lower
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Table 4. Mean ± SD skeletal muscle concentrations (lmol/g) of L-carnitine, acetyl-L-carnitine, and total L-carnitine in ESRD patients at
baseline and after 6, 12, and >12 months of hemodialysis treatment
ESRD patients
Analyte Baseline 6 months 12 months >12 months
L-carnitine 3.01 ± 0.47d 2.60 ± 0.57d 2.64 ± 0.52d 1.87 ± 0.67a,b,c
Acetyl-L-carnitine 1.52 ± 0.64c,d 1.71 ± 0.76c,d 0.914 ± 0.377a,b 0.727 ± 0.297a,b
Total L-carnitine 4.54 ± 0.88d 4.17 ± 1.01d 3.56 ± 0.93d 2.61 ± 0.91a,b,c
aCompared to ESRD patients at baseline, P < 0.05.
bCompared to ESRD patients after 6 months of dialysis, P < 0.05.
cCompared to ESRD patients after 12 months of dialysis, P < 0.05.
dCompared to ESRD patients after > 12 months of dialysis, P < 0.05.
than normal in a group of long-term hemodialysis pa-
tients. In contrast, Fagher et al [29] found that the levels
of L-carnitine in skeletal muscle from patients who had
been undergoing hemodialysis for an average of 3 years
were within the range of values encountered for healthy
adults. However, the authors of this paper warn that the
analytical method used for the 2 populations differed and
so no statistical comparisons were performed. Therefore,
the results of this latter study should not be taken as evi-
dence for a lack of effect of hemodialysis on skeletal mus-
cle L-carnitine content. Mingardi et al [30] also reported
that total and free muscle L-carnitine in hemodialysis pa-
tients was similar to control values but this was based on
data from just 4 patients, which do not allow a meaning-
ful comparison, particularly with the variability normally
encountered with muscle L-carnitine analysis.
For L-carnitine, the magnitude of the reduction (be-
tween baseline and the long-term dialysis patients) was
similar (30% to 40%) in both plasma and muscle. How-
ever, while the reduction in plasma levels occurred over
the first 12 months of hemodialysis, the most significant
change in muscle L-carnitine concentrations were de-
tected after 12 months. This is consistent with the con-
cept that L-carnitine in skeletal muscle equilibrates very
slowly with that in plasma [31]. This slow equilibration
arises because more than 98% of the body’s L-carnitine is
stored inside skeletal muscle, and the rate constant for the
efflux of the compound from muscle tissue is extremely
small [2, 31]. The other notable finding in the present
study is that in muscle, most of the total L-carnitine
could be accounted for as the sum of directly measured
L-carnitine and acetyl-L-carnitine, irrespective of the
sampling time (Table 4), whereas in plasma there was
a progressive accumulation of nonacetyl acylcarnitines
(Fig. 3). The implications of the accumulation of longer-
chain acylcarnitines in the plasma of these hemodialysis
patients are unknown.
The delayed temporal relationship between plasma
and muscle L-carnitine levels, described above, may ex-
plain why previous attempts to correlate plasma and
skeletal muscle levels of L-carnitine and related species
have met with limited success [9, 27, 32]. The disparate
time-courses can be explained by the compartmentaliza-
tion of L-carnitine in skeletal muscle and the slow kinet-
ics of L-carnitine distribution between plasma and tissue
[2, 8]. While the plasma compartment becomes dramati-
cally depleted of L-carnitine during a single dialysis ses-
sion [3, 8], the movement of L-carnitine from the rich
muscle stores during the intervening interdialysis period
serves to partially (but not totally) replenish the plasma
levels. With continued dialysis, there is a net removal of
L-carnitine from muscle tissue, leading to a gradual deple-
tion in this compartment. While acetyl-L-carnitine levels
also decline during hemodialysis treatment, the plasma
levels of this ester remain well above the normal range.
Other carnitine esters accumulate in plasma during long-
term hemodialysis treatment, meaning that there is a sig-
nificant change with time in the composition of a dialysis
patient’s plasma carnitine pool.
CONCLUSION
The present study provides definitive data showing a
dramatic reduction in plasma L-carnitine and acetyl-L-
carnitine levels upon the commencement of hemodialysis
treatment of ESRD patients. While these changes occur
primarily within the first few months of hemodialysis, it
may take 12 months or more for significant accumulation
of plasma (nonacetyl) esters of L-carnitine, and for a sig-
nificant decline in the skeletal muscle L-carnitine pool.
The lack of previous studies to find significant correla-
tions between plasma and muscle carnitine levels is likely
to be due, in large, to the different kinetic profiles for the
2 carnitine pools.
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